WO2004035762A3 - Microencapsulation and sustained release of biologically active polypeptides - Google Patents
Microencapsulation and sustained release of biologically active polypeptides Download PDFInfo
- Publication number
- WO2004035762A3 WO2004035762A3 PCT/US2003/033198 US0333198W WO2004035762A3 WO 2004035762 A3 WO2004035762 A3 WO 2004035762A3 US 0333198 W US0333198 W US 0333198W WO 2004035762 A3 WO2004035762 A3 WO 2004035762A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- biologically active
- sustained release
- active polypeptides
- microencapsulation
- compositions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
- A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2003282955A AU2003282955A1 (en) | 2002-10-17 | 2003-10-17 | Microencapsulation and sustained release of biologically active polypeptides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41938802P | 2002-10-17 | 2002-10-17 | |
US60/419,388 | 2002-10-17 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004035762A2 WO2004035762A2 (en) | 2004-04-29 |
WO2004035762A3 true WO2004035762A3 (en) | 2004-08-05 |
Family
ID=32108072
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/033168 WO2004036186A2 (en) | 2002-10-17 | 2003-10-17 | Microencapsulation and sustained release of biologically active polypeptides |
PCT/US2003/033062 WO2004035754A2 (en) | 2002-10-17 | 2003-10-17 | Microencapsulation and sustained release of biologically active polypeptides |
PCT/US2003/033198 WO2004035762A2 (en) | 2002-10-17 | 2003-10-17 | Microencapsulation and sustained release of biologically active polypeptides |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2003/033168 WO2004036186A2 (en) | 2002-10-17 | 2003-10-17 | Microencapsulation and sustained release of biologically active polypeptides |
PCT/US2003/033062 WO2004035754A2 (en) | 2002-10-17 | 2003-10-17 | Microencapsulation and sustained release of biologically active polypeptides |
Country Status (3)
Country | Link |
---|---|
US (4) | US7164005B2 (en) |
AU (3) | AU2003277446A1 (en) |
WO (3) | WO2004036186A2 (en) |
Families Citing this family (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6824822B2 (en) * | 2001-08-31 | 2004-11-30 | Alkermes Controlled Therapeutics Inc. Ii | Residual solvent extraction method and microparticles produced thereby |
US20040121009A1 (en) * | 2002-10-17 | 2004-06-24 | Alkermes Controlled Therapeutics, Inc. | Method of modifying the release profile of sustained release compositions |
US7164005B2 (en) * | 2002-10-17 | 2007-01-16 | Alkermes, Inc. | Microencapsulation and sustained release of biologically active polypeptides |
CA2533314C (en) | 2003-07-18 | 2013-07-09 | Oakwood Laboratories, L.L.C. | Prevention of molecular weight reduction of the polymer, impurity formation and gelling in polymer compositions |
US20060057180A1 (en) * | 2004-02-20 | 2006-03-16 | Ashutosh Chilkoti | Tunable nonfouling surface of oligoethylene glycol |
US20060110423A1 (en) * | 2004-04-15 | 2006-05-25 | Wright Steven G | Polymer-based sustained release device |
KR101040415B1 (en) * | 2004-04-15 | 2011-06-09 | 알케르메스,인코포레이티드 | Polymer-based sustained release device |
US7456254B2 (en) * | 2004-04-15 | 2008-11-25 | Alkermes, Inc. | Polymer-based sustained release device |
CA2565980A1 (en) | 2004-05-12 | 2005-12-01 | Luca Technologies, Llc | Generation of hydrogen from hydrocarbon-bearing materials |
NZ553149A (en) * | 2004-08-12 | 2010-01-29 | Quest Pharmaceutical Services | Use of inositol hexaphosphate or inositol hexasulphate to complex biologically active compounds for the preparation of controlled release pharmaceutical compositions |
US7597907B2 (en) * | 2004-11-05 | 2009-10-06 | Trustees Of The University Of Pennsylvania | Antioxidant polymer nanocarriers for use in preventing oxidative injury |
US11246913B2 (en) | 2005-02-03 | 2022-02-15 | Intarcia Therapeutics, Inc. | Suspension formulation comprising an insulinotropic peptide |
DK1888103T3 (en) * | 2005-04-11 | 2012-04-23 | Amylin Pharmaceuticals Inc | USE OF GLP-1, EXENDIN AND AGONISTS THEREOF TO DELAY OR PREVENT CARDIAL REMODELING |
EP1877439B1 (en) | 2005-04-18 | 2011-02-09 | Novo Nordisk A/S | Il-21 variants |
BRPI0611251A2 (en) * | 2005-06-06 | 2010-12-07 | Novo Nordisk As | composition, methods for stabilizing a composition comprising il-21, refolding unfolded or partially folded in solution il-21, purifying il-21 and treating cancer, and use of il-21 and sulfate |
CN100429227C (en) | 2005-06-29 | 2008-10-29 | 常州制药厂有限公司 | Exendin 4 polypeptide segment |
FI3524261T3 (en) | 2005-08-19 | 2024-01-11 | Amylin Pharmaceuticals Llc | Exendin for use in treating diabetes and reducing body weight |
KR20080043301A (en) * | 2005-09-14 | 2008-05-16 | 아레스 트레이딩 에스.에이. | Method for the quantitative determination of poloxamers |
HUE029798T2 (en) * | 2005-11-04 | 2017-03-28 | Glaxosmithkline Llc | Methods for administering hypoglycemic agents |
WO2007081321A1 (en) * | 2006-01-09 | 2007-07-19 | Alkermes, Inc. | Ac2993 lar dosing regimen |
US7416879B2 (en) * | 2006-01-11 | 2008-08-26 | Luca Technologies, Inc. | Thermacetogenium phaeum consortium for the production of materials with enhanced hydrogen content |
US7977282B2 (en) | 2006-04-05 | 2011-07-12 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
US7696132B2 (en) | 2006-04-05 | 2010-04-13 | Luca Technologies, Inc. | Chemical amendments for the stimulation of biogenic gas generation in deposits of carbonaceous material |
EP3255149A3 (en) * | 2006-05-02 | 2018-04-18 | Intrexon Actobiotics NV | Microbial intestinal delivery of obesity related peptides |
RU2456018C2 (en) | 2006-07-11 | 2012-07-20 | КьюПиЭс, ЭлЭлСи | Prolonged-release pharmaceutical compositions for peptide delivery |
ES2422864T3 (en) | 2006-08-09 | 2013-09-16 | Intarcia Therapeutics, Inc | Osmotic release systems and piston units |
AU2007310777A1 (en) | 2006-10-26 | 2008-05-02 | Novo Nordisk A/S | IL-21 variants |
WO2008061355A1 (en) * | 2006-11-24 | 2008-05-29 | Matregen Corp. | Glp-1 depot systems, and methods of manufacture and uses thereof |
CA2671665A1 (en) * | 2006-12-21 | 2008-06-26 | Novo-Nordisk A/S | Interleukin-21 variants with altered binding to the il-21 receptor |
JP2010522196A (en) * | 2007-03-22 | 2010-07-01 | アルカームズ,インコーポレイテッド | Coacervation process |
KR100805208B1 (en) * | 2007-03-27 | 2008-02-21 | 주식회사 펩트론 | Composition and microsphere for controlled-release of exendin and method of preparing the same |
WO2008133908A2 (en) | 2007-04-23 | 2008-11-06 | Intarcia Therapeutics, Inc. | Suspension formulations of insulinotropic peptides and uses thereof |
WO2008157540A1 (en) * | 2007-06-20 | 2008-12-24 | Alkermes, Inc. | Quench liquids and washing systems for production of microparticles |
US8568786B2 (en) * | 2007-10-27 | 2013-10-29 | The Trustees Of The Universtiy Of Pennsylvania | Method and compositions for polymer nanocarriers containing therapeutic molecules |
US7927629B2 (en) * | 2007-10-27 | 2011-04-19 | The Trustees Of The University Of Pennsylvania | Method and compositions for polymer nanocarriers containing therapeutic molecules |
EP2240155B1 (en) | 2008-02-13 | 2012-06-06 | Intarcia Therapeutics, Inc | Devices, formulations, and methods for delivery of multiple beneficial agents |
ES2552646T3 (en) | 2008-05-21 | 2015-12-01 | Amylin Pharmaceuticals, Inc. | Exendins to lower cholesterol and triglycerides |
SG10201703039SA (en) | 2008-09-04 | 2017-05-30 | Amylin Pharmaceuticals Llc | Sustained release formulations using non-aqueous carriers |
WO2011037623A1 (en) | 2009-09-28 | 2011-03-31 | Intarcia Therapeutics, Inc. | Rapid establishment and/or termination of substantial steady-state drug delivery |
CN102770152B (en) | 2009-11-25 | 2016-07-06 | 阿瑞斯根股份有限公司 | The mucosal delivery of peptides |
BRPI1003424A2 (en) * | 2010-09-08 | 2013-01-08 | Univ Rio De Janeiro | human amylin containment polymeric system and agonist analogs, process and use; functional assessment process of released amylin |
WO2012087492A2 (en) * | 2010-12-23 | 2012-06-28 | Tailorpill Technologies, Llc | System and methods for personalized pill compounding |
US20120208755A1 (en) | 2011-02-16 | 2012-08-16 | Intarcia Therapeutics, Inc. | Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers |
JP2014520159A (en) * | 2011-06-24 | 2014-08-21 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニー | Method for treating diabetes with sustained-release preparation of GLP-1 receptor agonist |
CN102488619B (en) * | 2011-12-05 | 2014-08-06 | 上海交通大学 | Device for continuously producing exenatide microspheres and method for controlling release rate of microspheres |
WO2014027254A1 (en) | 2012-08-14 | 2014-02-20 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
EP2934562A1 (en) | 2012-08-14 | 2015-10-28 | Wockhardt Limited | Pharmaceutical microparticulate compositions of polypeptides |
CN104840415B (en) | 2014-02-19 | 2019-03-15 | 香港浸会大学 | Long-acting controlled release lipidosome gel composition containing blood-sugar decreasing active and preparation method thereof |
US9889085B1 (en) | 2014-09-30 | 2018-02-13 | Intarcia Therapeutics, Inc. | Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c |
US10537373B2 (en) * | 2015-04-24 | 2020-01-21 | Biomet Sports Medicine, Llc | Porous implants with injectable capabilities |
CN113598842A (en) | 2015-06-03 | 2021-11-05 | 因塔西亚制药公司 | Implant placement and removal system |
EP3458084B1 (en) | 2016-05-16 | 2020-04-01 | Intarcia Therapeutics, Inc | Glucagon-receptor selective polypeptides and methods of use thereof |
USD860451S1 (en) | 2016-06-02 | 2019-09-17 | Intarcia Therapeutics, Inc. | Implant removal tool |
USD840030S1 (en) | 2016-06-02 | 2019-02-05 | Intarcia Therapeutics, Inc. | Implant placement guide |
EP3565580B1 (en) | 2017-01-03 | 2024-03-06 | i2o Therapeutics, Inc. | Continuous administration of exenatide and co-adminstration of acetaminophen, ethinylestradiol or levonorgestrel |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US6190702B1 (en) * | 1996-03-28 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase |
Family Cites Families (43)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US28733A (en) * | 1860-06-19 | Game-box | ||
NL280825A (en) | 1962-07-11 | |||
BE744162A (en) * | 1969-01-16 | 1970-06-15 | Fuji Photo Film Co Ltd | ENCAPSULATION PROCESS |
DE2010115A1 (en) * | 1970-03-04 | 1971-09-16 | Farbenfabriken Bayer Ag, 5090 Leverkusen | Process for the production of micro-granules |
JPS523342B2 (en) * | 1972-01-26 | 1977-01-27 | ||
GB1413186A (en) | 1973-06-27 | 1975-11-12 | Toyo Jozo Kk | Process for encapsulation of medicaments |
US4530840A (en) | 1982-07-29 | 1985-07-23 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US4542025A (en) | 1982-07-29 | 1985-09-17 | The Stolle Research And Development Corporation | Injectable, long-acting microparticle formulation for the delivery of anti-inflammatory agents |
US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
US5225205A (en) * | 1989-07-28 | 1993-07-06 | Debiopharm S.A. | Pharmaceutical composition in the form of microparticles |
EP0489843A4 (en) | 1989-08-28 | 1992-08-12 | Pharmaceutical Delivery Systems, Inc. | Bioerodible polymers useful for the controlled release of therapeutic agents |
US5707644A (en) | 1989-11-04 | 1998-01-13 | Danbiosyst Uk Limited | Small particle compositions for intranasal drug delivery |
US5126147A (en) * | 1990-02-08 | 1992-06-30 | Biosearch, Inc. | Sustained release dosage form |
GB9020544D0 (en) * | 1990-09-20 | 1990-10-31 | Sandoz Ltd | Improvements in or relating to organic compounds |
US5912015A (en) * | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5922340A (en) | 1992-09-10 | 1999-07-13 | Children's Medical Center Corporation | High load formulations and methods for providing prolonged local anesthesia |
US5700485A (en) | 1992-09-10 | 1997-12-23 | Children's Medical Center Corporation | Prolonged nerve blockade by the combination of local anesthetic and glucocorticoid |
WO1994005265A1 (en) | 1992-09-10 | 1994-03-17 | Children's Medical Center Corporation | Biodegradable polymer matrices for sustained delivery of local anesthetic agents |
US5672659A (en) | 1993-01-06 | 1997-09-30 | Kinerton Limited | Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
DK0686045T3 (en) | 1993-02-23 | 2001-03-05 | Genentech Inc | Stabilization of organic solvent-treated polypeptides with an adjuvant |
US5981719A (en) * | 1993-03-09 | 1999-11-09 | Epic Therapeutics, Inc. | Macromolecular microparticles and methods of production and use |
US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
US5385887A (en) * | 1993-09-10 | 1995-01-31 | Genetics Institute, Inc. | Formulations for delivery of osteogenic proteins |
AU677115B2 (en) | 1994-12-19 | 1997-04-10 | University Of Miami | Biodegradable injectable drug delivery polymer |
US5834428A (en) * | 1995-04-14 | 1998-11-10 | 1149336 Ontario Inc. | Glucagon-like peptide-2 and its therapeutic use |
US5922253A (en) | 1995-05-18 | 1999-07-13 | Alkermes Controlled Therapeutics, Inc. | Production scale method of forming microparticles |
US6369116B1 (en) | 1995-06-02 | 2002-04-09 | Oculex Pharmaceuticals, Inc. | Composition and method for treating glaucoma |
GB9513118D0 (en) | 1995-06-28 | 1995-08-30 | Merck Sharp & Dohme | Therapeutic agents |
CA2192782C (en) | 1995-12-15 | 2008-10-14 | Nobuyuki Takechi | Production of microspheres |
US6096728A (en) * | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
CN1126537C (en) | 1996-05-23 | 2003-11-05 | 株式会社三养社 | Locally administrable, biodegradable and sustained-release pharmaceutical composition for periodontitis and process for preparation thereof |
JP2000516912A (en) * | 1996-06-05 | 2000-12-19 | ロシュ ダイアグノスティクス ゲゼルシャフト ミット ベシュレンクテル ハフツング | Exendin analogs, methods for their preparation and formulations containing them |
US6046187A (en) | 1996-09-16 | 2000-04-04 | Children's Medical Center Corporation | Formulations and methods for providing prolonged local anesthesia |
AU5696198A (en) * | 1996-12-06 | 1998-06-29 | Amgen, Inc. | Combination therapy using a tnf binding protein for treating tnf-mediated diseases |
CA2277112C (en) * | 1997-01-07 | 2008-08-26 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the reduction of food intake |
US6203813B1 (en) | 1997-01-13 | 2001-03-20 | Lance L. Gooberman | Pharmaceutical delivery device and method of preparation therefor |
US6113947A (en) * | 1997-06-13 | 2000-09-05 | Genentech, Inc. | Controlled release microencapsulated NGF formulation |
WO1999001114A1 (en) | 1997-07-02 | 1999-01-14 | Euro-Celtique, S.A. | Prolonged anesthesia in joints and body spaces |
US6506724B1 (en) * | 1999-06-01 | 2003-01-14 | Amylin Pharmaceuticals, Inc. | Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus |
US6465425B1 (en) | 2000-02-10 | 2002-10-15 | Alkermes Controlled Therapeutics, Inc. | Microencapsulation and sustained release of biologically active acid-stable or free sulfhydryl-containing proteins |
EP1390061A2 (en) * | 2000-12-13 | 2004-02-25 | Eli Lilly And Company | Chronic treatment regimen using glucagon-like insulinotropic peptides |
NZ535008A (en) | 2002-02-08 | 2005-09-30 | Alkermes Inc | Polymer-based compositions for sustained release |
US7164005B2 (en) * | 2002-10-17 | 2007-01-16 | Alkermes, Inc. | Microencapsulation and sustained release of biologically active polypeptides |
-
2003
- 2003-10-17 US US10/688,786 patent/US7164005B2/en not_active Expired - Lifetime
- 2003-10-17 WO PCT/US2003/033168 patent/WO2004036186A2/en not_active Application Discontinuation
- 2003-10-17 US US10/688,059 patent/US7462365B2/en active Active
- 2003-10-17 AU AU2003277446A patent/AU2003277446A1/en not_active Abandoned
- 2003-10-17 AU AU2003282955A patent/AU2003282955A1/en not_active Abandoned
- 2003-10-17 WO PCT/US2003/033062 patent/WO2004035754A2/en not_active Application Discontinuation
- 2003-10-17 AU AU2003286472A patent/AU2003286472A1/en not_active Abandoned
- 2003-10-17 WO PCT/US2003/033198 patent/WO2004035762A2/en not_active Application Discontinuation
-
2006
- 2006-09-29 US US11/541,323 patent/US20070027085A1/en not_active Abandoned
-
2008
- 2008-11-06 US US12/289,857 patent/US8129339B2/en active Active
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4389330A (en) * | 1980-10-06 | 1983-06-21 | Stolle Research And Development Corporation | Microencapsulation process |
US5019400A (en) * | 1989-05-01 | 1991-05-28 | Enzytech, Inc. | Very low temperature casting of controlled release microspheres |
US5656297A (en) * | 1992-03-12 | 1997-08-12 | Alkermes Controlled Therapeutics, Incorporated | Modulated release from biocompatible polymers |
US6190702B1 (en) * | 1996-03-28 | 2001-02-20 | Takeda Chemical Industries, Ltd. | Sustained-released material prepared by dispersing a lyophilized polypeptide in an oil phase |
Also Published As
Publication number | Publication date |
---|---|
AU2003277446A1 (en) | 2004-05-04 |
US20040228833A1 (en) | 2004-11-18 |
AU2003282955A1 (en) | 2004-05-04 |
US20040208929A1 (en) | 2004-10-21 |
AU2003286472A1 (en) | 2004-05-04 |
WO2004035754A2 (en) | 2004-04-29 |
US8129339B2 (en) | 2012-03-06 |
US7462365B2 (en) | 2008-12-09 |
WO2004035762A2 (en) | 2004-04-29 |
AU2003277446A8 (en) | 2004-05-04 |
WO2004036186A2 (en) | 2004-04-29 |
WO2004035754A3 (en) | 2004-10-07 |
WO2004036186A3 (en) | 2004-12-23 |
US7164005B2 (en) | 2007-01-16 |
US20070027085A1 (en) | 2007-02-01 |
AU2003286472A8 (en) | 2004-05-04 |
AU2003282955A8 (en) | 2004-05-04 |
US20090281034A1 (en) | 2009-11-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2004035754A3 (en) | Microencapsulation and sustained release of biologically active polypeptides | |
LU91989I9 (en) | ||
AU2003228809A1 (en) | Kinase anchor protein muteins, peptides thereof, and related methods | |
WO2005045001A3 (en) | Insulin-producing cells derived from stem cells | |
NO20065213L (en) | Poly (lactide-co-glycolide) -based sustained-release microcapsules comprising a polypeptide and a sugar | |
WO2005009381A3 (en) | Immediate-release formulation of acid-labile pharmaceutical compositions | |
WO2006071840A8 (en) | Formulations of human growth hormone comprising a non-naturally encoded amino acid | |
WO2006023665A3 (en) | Il-1 antagonist formulations | |
WO2007087053A3 (en) | Bmp-7 variant compositions, methods and uses | |
MXPA03008420A (en) | Solid orally-dispersible pharmaceutical formulation. | |
WO2005105740A3 (en) | Preparation of tegaserod and tegaserod maleate | |
WO2001078682A3 (en) | Sustained release drug compositions | |
AU2003281358A1 (en) | Pin1 peptidyl-prolyl isomerase polypeptides, their crystal structures, and use thereof for drug design | |
AU2003215708A1 (en) | Orodispersible pharmaceutical composition comprising perindopril | |
WO2002062856A3 (en) | Microencapsulated biologically active substances that contain a water-soluble or water-dispersible comb polymer | |
AU2003219569A1 (en) | Antimicrobial peptide, its analogs and antimicrobial composition comprising them | |
WO2003006492A3 (en) | Biologically active peptides | |
AU2003269871A1 (en) | Radiosensitizer composition containing n-acetylphytosphingosine analogs and n,n-dimethyl-phytosphingosine analogs as the active ingredients | |
AP2004003193A0 (en) | Microcapsules for the delayed, controlled relese of perindopril. | |
MY138799A (en) | Orodispersible pharmaceutical composition of an antithrombotic compound | |
WO2003074656A3 (en) | Rank-ligand-induced sodium/proton antiporter polypeptides | |
EP1571148A4 (en) | 3-phenyl-cinnoline homologue and antitumor agent containing the same | |
WO2002066513A3 (en) | Human circulating lekti fragments hf7072, hf7638 and hf14448 and use thereof | |
WO2003048206A3 (en) | Growth hormone agonist peptides and their uses | |
AU2002368307A1 (en) | Soluble truncated polypeptides of the nogo-a protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |